| Intervention type | Specific intervention | Mechanism / rationale | Evidence type | Key findings / outcomes | Limitations / notes | Key citations | URL and publication date |
|---|---|---|---|---|---|---|---|
| Supportive | Symptomatic management of myoclonus and seizures | No disease-modifying therapy is established; care focuses on controlling neurologic symptoms in surviving type II patients | Human clinical practice / review | Recent preclinical review states patients with sialidosis currently receive “supportive care and symptomatic relief, primarily for the management of myoclonus and seizures” | Evidence is descriptive rather than protocolized; especially relevant to infantile/juvenile type II rather than lethal hydropic congenital presentations | (pqac-00000015, pqac-00000011) | https://doi.org/10.1101/2023.11.10.566667 ; posted 2023-11-13 / cited as 2024 preprint |
| Supportive | Multidisciplinary monitoring in natural history protocols | Longitudinal neurologic, ophthalmologic, imaging, electrophysiologic, biochemical, and functional assessments help define progression and future trial endpoints | Observational trial / real-world implementation | NIH natural history protocol enrolls enzyme- or DNA-confirmed sialidosis/galactosialidosis patients and uses MRI/MRS, hearing testing, EEG, EMG/NCV, echocardiogram, abdominal ultrasound, ophthalmology, rehabilitation, speech, neurology, psychology, and biomarker sampling | Observational only; not a treatment; includes all sialidosis forms rather than congenital type II specifically | (pqac-00000026) | https://clinicaltrials.gov/study/NCT00029965 ; first posted 2002-01-28, recruiting update 2026-05-29 |
| Experimental | Recombinant NEU1 enzyme replacement therapy (ERT) | Replaces deficient lysosomal neuraminidase-1 to reduce storage of sialylated glycoproteins / oligosaccharides | Mouse preclinical | Review summarizes “short-term ERT” in Neu1−/− mice using recombinant Neu1 from insect cells; corrected systemic pathology in mice | Strong immunogenicity limited durability/translation; no approved human ERT for sialidosis | (pqac-00000013, pqac-00000014, pqac-00000019, pqac-00000020) | https://doi.org/10.3390/jcm9030695 ; 2020-03-04 |
| Experimental | PPCA-based pharmacologic chaperone approach | NEU1 requires protective protein/cathepsin A (PPCA) for folding, lysosomal localization, stability, and activation; augmenting PPCA can rescue residual mutant NEU1 | In vitro and mouse preclinical | Recombinant PPCA and related chaperone strategies produced small but consistent increases in residual NEU1 activity in patient fibroblasts; prior AAV-PPCA work improved residual activity and prevented kidney pathology / oligosacchariduria in a type I model | Likely most applicable where residual NEU1 is present; evidence strongest for type I or attenuated variants, not fully null congenital cases | (pqac-00000004, pqac-00000015, pqac-00000035, pqac-00000041) | https://doi.org/10.3390/jcm9030695 ; 2020-03-04 |
| Experimental | AAV-PPCA chaperone-mediated gene therapy | Liver-directed PPCA expression acts as a systemic chaperone to enhance residual NEU1 function | Mouse preclinical | Prior work cited in the 2024 preprint showed a single liver-specific AAV-PPCA dose “enhanced residual Neu1 activity and prevented kidney pathology and oligosacchariduria” | Mutation-dependent; mainly relevant to residual-activity alleles rather than severe congenital null alleles | (pqac-00000015, pqac-00000014) | https://doi.org/10.1101/2023.11.10.566667 ; posted 2023-11-13 / cited as 2024 preprint |
| Experimental | Dual AAV gene therapy (NEU1 + PPCA; scAAV2/8 co-injection) | Directly restores NEU1 plus its required chaperone PPCA, aiming to correct enzyme deficiency, storage, lysosomal exocytosis, fibrosis, and neurovisceral pathology | Mouse preclinical | In Neu1−/− mice, treated animals were “phenotypically indistinguishable from their WT controls,” with restored NEU1 activity in most tissues, reversal of sialyl-oligosacchariduria, diminished/absent vacuolization in visceral organs and brain, normalization of lysosomal exocytosis, and prevention of generalized fibrosis | Preclinical bioRxiv study; not yet a human trial; long-term durability, dosing, immunity, and CNS translation remain to be established | (pqac-00000011, pqac-00000015, pqac-00000036) | https://doi.org/10.1101/2023.11.10.566667 ; posted 2023-11-13 / cited as 2024 preprint |
| Experimental | Pharmacologic proteostasis / proteasome inhibition (e.g., MG132; celastrol discussed in review) | May improve folding, trafficking, and lysosomal localization of defective NEU1 proteins | In vitro / preclinical | Review notes MG132 “enhances enzyme activity and its localization in cells expressing defective sialidase”; celastrol and other compounds were explored as adjunctive approaches | Early-stage only; toxicity and translational feasibility uncertain; not specific to congenital type II | (pqac-00000014, pqac-00000019) | https://doi.org/10.3390/diagnostics8020029 ; 2018-04-20 |
| Experimental / adjunctive | Dietary betaine supplementation | Proposed to stabilize residual mutant NEU1 and improve oligosaccharide handling | Mouse preclinical and patient fibroblasts | In residual-activity mouse models, betaine increased mutant NEU1 levels and resolved oligosacchariduria; patient fibroblasts showed small activity gains with several compounds | Data are primarily for type I / residual-activity disease, not severe congenital type II | (pqac-00000004, pqac-00000013) | https://doi.org/10.3390/jcm9030695 ; 2020-03-04 |
| Supportive / preventive | Carrier detection, prenatal molecular diagnosis, genetic counseling | Because congenital hydropic type II can be lethal prenatally or neonatally, family-based molecular diagnosis supports reproductive planning and early diagnosis | Human clinical genetics | Review recommends “carrier detection in affected families, prenatal molecular diagnosis, and improved genetic counseling”; congenital cases have been diagnosed prenatally in reported literature | Prevents recurrence risk rather than treating affected fetus/newborn; requires known familial variants or robust molecular testing | (pqac-00000014, pqac-00000033, pqac-00000030) | https://doi.org/10.3390/diagnostics8020029 ; 2018-04-20 |
| Real-world research infrastructure | Biomarker and cell-model development within natural history studies | Builds outcome measures and translational platforms for future therapy testing | Observational trial / translational implementation | NIH protocol collects CSF, blood, urine biomarkers; establishes fibroblast cultures for “testing potential therapeutic agents” and creates iPSC-derived neural tissues for mechanistic and preclinical work | Indirect therapeutic value; no interventional efficacy results yet | (pqac-00000017, pqac-00000026) | https://clinicaltrials.gov/study/NCT00029965 ; first posted 2002-01-28, recruiting update 2026-05-29 |


*Table: This table summarizes the current management landscape for sialidosis type II, from symptomatic care to preclinical gene therapy and enzyme/chaperone approaches. It also includes natural-history study infrastructure that is already being used in practice to support biomarker discovery and future interventional trials.*